NL-OMON23035已完成不适用
Effectiveness of Zometa® treatment for the prevention of bone metastases in high risk prostate cancer patients. A randomized, open-label, multicenter study of the European Association of Urology (EAU) in Cooperation with the Scandinavian Prostate Cancer Group (SPCG) and the Arbeitsgemeinschaft Urologische Onkologie (AUO). Protocol No. CZOL446G DE08.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,300
研究概览
简要总结
Wirth et al. Prevention of bone metastases in patients with high-risk non metastatic prostate cancer treated with Zoledronic Acid: Efficacy and safety results of the Zometa EUropean Study (ZEUS). Eur. Urol. 67 (2015) 482–491. http://dx.doi.org/10.1016/j.eururo.2014.02.014
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male patients aged 18+, ECOG = 0 (Karnofsky performance status > 90);
- •2. M0 prostate cancer patients who previously received local curative treatment (e.g. surgery, radiotherapy) or no local curative treatment. Duration between local curative treatment and starting of the study drug must not be longer than 6 months;
排除标准
- •1. Patients with known visceral metastasis or bone metastases in bone scan;
- •2. Prior treatment with bisposphonates;
研究者
相似试验
终止
2 期
Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone MarrowPrimary Breast CancerNCT00172068Novartis Pharmaceuticals96
终止
3 期
Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No SymptomsProstate CancerNCT00005073Novartis Pharmaceuticals544
已完成
3 期
Effectiveness of Zometa® treatment for the prevention of bone metastases in high risk prostate cancer patientsC61Malignant neoplasm of prostateprostate cancerDRKS00004981European Association of Urology1,433
已完成
不适用
Effectiveness of Zometa® treatment for the prevention of bone metastases in high risk prostate cancer patients: a randomised, open-label, multicentre study of the European Association of Urology (EAU) in Cooperation with the Scandinavian Prostate Cancer Group (SPCG) and the Arbeitsgemeinschaft Urologische Onkologie (AUO)Malignant neoplasm of the prostateCancerProstate cancerISRCTN66626762European Association of Urology (The Netherlands)1,300
已完成
2 期
Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant GliomaBrain TumorsCentral Nervous System(CNS)MalignanciesOsteoporosisNCT00301873Duke University60